Global Acute Lymphoblastic Leukemia Market 2016 to 2026 - Featuring Pfizer, Novartis AG, Sanofi & Amgen Among Others - ResearchAndMarkets.com

DUBLIN--()--The "Acute Lymphoblastic Leukemia Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026" report has been added to ResearchAndMarkets.com's offering.

This report analyzes the current and future scenario of the global acute lymphoblastic leukemia market. An increase in patient population with acute lymphoblastic leukemia, expansion of the pharmaceutical industry, improvement in health care infrastructure, and increase in the number of clinical trials are projected to be major drivers of the global market during the forecast period.

A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market.

This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global acute lymphoblastic leukemia market.

Global Acute Lymphoblastic Leukemia Market: Key Segments

In terms of type, the global acute lymphoblastic leukemia market has been classified into B-cell and T-cell. Based on treatment, the global acute lymphoblastic leukemia market has been segregated into chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. The segments have been analyzed based on available drug product used during the treatment of acute lymphoblastic leukemia, cost-effectiveness, and preference for industries.

In terms of end-user, the global market has been divided into hospitals, clinics, and others. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Acute Lymphoblastic Leukemia Market: Regional Outlook

In terms of region, the global acute lymphoblastic leukemia market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa).

The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Key Topics Covered:

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary

4. Market Overview

5. Market Dynamics

6. Global Acute Lymphoblastic Leukemia Market, by Type

7. Global Acute Lymphoblastic Leukemia Market, by Treatment

8. Global Acute Lymphoblastic Leukemia Market, by End-user

9. Acute Lymphoblastic Leukemia Market Analysis, by Region

10. North America Acute Lymphoblastic Leukemia Market

10.1. Key Findings

10.2. North America Acute Lymphoblastic Leukemia Market Overview

10.3. North America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country

10.4. North America Acute Lymphoblastic Leukemia Market Value Forecast, by Country

10.4.1. U.S.

10.4.2. Canada

10.5. North America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type

10.6. North America Acute Lymphoblastic Leukemia Market Value Forecast, by Type

10.6.1. B-cell

10.6.2. T-cell

10.7. North America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment

10.8. North America Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment

10.8.1. Chemotherapy

10.8.2. Radiation Therapy

10.8.3. Bone Marrow Transplant

10.8.4. Targeted Therapy

10.8.5. Immunotherapy

10.9. North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user

10.10. North America Acute Lymphoblastic Leukemia Market Forecast, End-user

10.10.1. Hospitals

10.10.2. Clinics

10.10.3. Others

10.11. North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

11. Europe Acute Lymphoblastic Leukemia Market

12. Asia Pacific Acute Lymphoblastic Leukemia Market

13. Latin America Acute Lymphoblastic Leukemia Market

14. Middle East & Africa Acute Lymphoblastic Leukemia Market

15. Competition Landscape

15.1. Acute Lymphoblastic Leukemia Market Share Analysis, by Company

15.2. Competition Matrix

15.3. Company Profile

15.3.1. Pfizer, Inc.

15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.1.2. Financial Overview

15.3.1.3. Product Portfolio

15.3.1.4. SWOT Analysis

15.3.1.5. Strategic Overview

15.3.2. Novartis AG

15.3.3. F. Hoffmann-La Roche Ltd.

15.3.4. Sanofi

15.3.5. Erytech Pharma Inc.

15.3.6. CELGENE CORPORATION

15.3.7. Amgen, Inc.

15.3.8. Bristol-Myers Squibb Company

15.3.9. Spectrum Pharmaceuticals, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/66js1s

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900